Implementation of HPV-based screening in Burkina Faso: lessons learned from the PARACAO hybrid-effectiveness study

Keitly Mensah1*, Charles Kaboré2, Salifou Zeba3, Magali Bouchon4, Véronique Duchesne1, Dolorès Pourette1, Pierre DeBeaudrap1 and Alexandre Dumont1

Abstract

Background: Cervical cancer screening in sub-Saharan countries relies on primary visual inspection with acetic acid (VIA). Primary human papillomavirus (HPV)-based screening is considered a promising alternative. However, the implementation and real-life effectiveness of this strategy at the primary-care level in limited-resource contexts remain under explored. In Ouagadougou, Burkina Faso, free HPV-based screening was implemented in 2019 in two primary healthcare centers. We carried out a process and effectiveness evaluation of this intervention.

Methods: Effectiveness outcomes and implementation indicators were assessed through a cohort study of screened women, observations in participating centers, individual interviews with women and healthcare providers and monitoring reports. Effectiveness outcomes were screening completeness and women's satisfaction. Logistic regression models and concurrent qualitative analysis explored how implementation variability, acceptability by women and the context affected effectiveness outcomes.

Results: After a 3-month implementation period, of the 350 women included in the cohort, 94% completed the screening, although only 26% had their screening completed in a single visit as planned in the protocol. The proportion of highly satisfied women was higher after result disclosure (95%) than after sampling (65%). A good understanding of the screening results and recommendations increased screening completeness and women's satisfaction, while time to result disclosure decreased satisfaction. Adaptations were made to fit healthcare workers' workload.

Conclusion: Free HPV-based screening was successfully integrated within primary care in Ouagadougou, Burkina Faso, leading to a high level of screening completeness despite the frequent use of multiple visits. Future implementation in primary healthcare centers needs to improve counseling and reduce wait times at the various steps of the screening sequence.

Keywords: Implementation, Cervical cancer, Process evaluation, Sub-saharan africa, HPV screening, Mixed-method
human papillomavirus (HPV) detection either alone or combined to screen for cervical precancerous or cancerous lesions at an early stage. Cytological screening was initiated in European countries in the mid-twentieth century and led to a dramatic reduction in the incidence and mortality of CC [3]. Because of its high cost, primary VIA was considered a more cost-effective alternative to be implemented on a large scale in LMICs. However, this strategy showed mitigated success mainly because it requires substantial labor and because its performance can be highly variable [4, 5]. More recently, evidence from two randomized controlled trials in India and South Africa has shown the superiority of primary HPV screening over primary VIA screening to prevent CC occurrence [6, 7], but it is unknown whether primary HPV testing can be successfully replicated in countries characterized by low income, high mortality and weak health systems.

Burkina Faso exemplifies such a situation. Primary VIA screening was implemented at the national level a decade ago, but its effects on reducing CC incidence remain unclear [8]. In this context, the Partnership for Action and Research against Cervical Cancer in West Africa (PARACAO) project launched by the nongovernmental organization (NGO) Doctors of The World (DOTW) aims to introduce HPV-based screening at the primary health care level in Ouagadougou, the main city of Burkina Faso. The intervention was based on the premise that primary HPV screening and subsequent management (triage and treatment) should be performed on the same day, the so-called “screen-and-treat” approach, to increase women's chance of being fully screened and treated [9].

Our primary hypothesis was that the PARACAO could lead to high screening completion among eligible women. The secondary hypothesis was that this new screening is well accepted by women.

The purpose of this study was to simultaneously assess the PARACAO implementation process and its effect on screening completeness and women's satisfaction to understand the mechanisms underlying the impact of the intervention. We also aimed to examine the effects of contextual factors on implementation and effectiveness outcomes to help implementers design effective implementation strategies.

**Methods**

**Context**

In 2010, the estimated annual incidence of CC in Burkina Faso reached 1230 women diagnosed and 838 deaths from the disease. As the leading cause of cancer mortality among women in the country [10, 11], the Ministry of Health considered CC a public health priority in 2011, resulting in many actions at the local and national levels. Since April 2016, CC screening has been included as a free service of the national health package for women. In Burkina Faso, the decentralized health system is divided into three levels. The peripheral level operates at the community and district level, providing basic preventive and curative care, it is the entry point in the health system. When necessary, patients can be referred from the primary level to the intermediate or central level, which consists, respectively, of regional hospitals and university or national hospitals [12]. Additionally, biomedical services are divided between public and private (including traditional health practitioners) sectors.

Currently, the national CC control strategy relies on VIA screening and cryotherapy delivered at primary and secondary healthcare facilities nationwide. In addition to VIA screening, colposcopy and more advanced treatment (LEEP, hysterectomy) are available in some private clinics or in the university hospitals of the two main cities (Ouagadougou and Bobo Dioulasso). Despite being covered by the national health plan, women are often required to pay between $1 and 4 US dollars to receive screening because of recurrent shortages in material supply (speculums and gas for cryotherapy) [13].

**Description of PARACAO intervention and its implementation strategy**

The PARACAO was developed based on WHO guidelines and on a baseline of formative research [14] (see Additional file 1: Table S1).

The screening strategy included primary HPV testing, triage of HPV-positive women with VIA and prompt treatment of women at need. HPV testing was available either through self-performed or midwife-performed collection of vaginal specimens.

Women with VIA-positive lesions that fulfilled the International Agency for Research on Cancer (IARC) criteria for cryotherapy [14] were supposed to be immediately treated with thermal ablation. Otherwise, they were referred to an identified clinic for the appropriate treatment with the full cost covered by DOTW.

The entire screening process – from HPV testing to result disclosure, VIA and treatment if needed – was set to be delivered in a single visit, according to the “screen-and-treat” approach (Fig. 1).

The intervention was implemented in 2019 in two urban primary healthcare centers in Ouagadougou. Their general characteristics are shown in Table 1. These sites are believed to be similar to other urban primary health centers in terms of population, activity, staff and equipment. The intervention targeted women attending these health facilities for CC screening or for other healthcare services (family planning, child vaccination, or gynecological issues). Women were considered eligible for
HPV-based screening if they were aged 25–55 years old and had no hysterectomy. If they had ongoing menstruation and/or genital infection at the time of the screening, they were considered temporarily ineligible until the condition was resolved. There were no specific geographic criteria for recruitment.

The PARACAO implementation strategy was embedded within the usual model of care delivery of the participating healthcare facilities. Table 2 shows the theoretical framework of the PARACAO. Four components were implemented in each participating facility from May to December 2019 (Fig. 1):

**Component 1 – Integration of healthcare services** – The Burkina-based DOTW program coordinator provided changes in structure and equipment required for HPV testing within each participating facility. It consisted of the identification of dedicated rooms for CC screening, building rehabilitation to fit the Genexpert platform requirement (dust, temperature and space) [15] and adequate equipment provision (HPV sampling kits, VIA kits, thermal ablation material, GeneXpert platform, cartridges, furniture, and day-to-day supplies) for the intervention. Tasks for HPV testing were integrated into healthcare providers’ (laboratory staff and midwives) workload to deliver a “screen-and treat” approach.

**Component 2 – Education of healthcare providers** – The DOTW program coordinator organized staff training. Laboratory staff received 5-day off-site training conducted by the CEPHEID training team and a member of the National Tuberculosis Laboratory, who was trained and an expert in the use of GeneXpert. All midwives at participating sites received off-site three-block training. Each training block lasted for 5 days, was conducted by national experts and DOTW national staff and addressed a specific topic: CC screening in general, VIA realization or HPV-based strategy with counseling and sampling options (self or midwife performed).

**Component 3 – Educational outreach visits** – Weekly supervisory visits to each participating facility were intended to ensure that the screening delivery protocol was followed, to assess the fidelity of the project implementation, to identify barriers to implementation and possible strategies to overcome barriers, to reinforce healthcare provider competencies and to verify document and data quality. These visits were performed by DOTW supervisors, and the connection between healthcare providers and supervisors was facilitated by a midwife, identified as a focal point (FP).

In addition, a member of the National Tuberculosis Laboratory, who was trained and an expert in the use of GeneXpert, performed the monthly supervisions of the laboratory staff.

**Component 4 – Patient counseling** – Midwives delivered counseling regarding CC screening to women during their first visit to the participating facility. Part of this counseling consisted of offering the choice between two methods of vaginal sampling for HPV testing: self-performed or midwife-performed collection. Counseling was repeated at each step of the screening process (post-HPV test results, post-VIA and posttreatment) to persuade women to adhere to care management and recommendations. The screening process was entirely free.

All staff (laboratory and midwives) were involved in HPV-based CC screening without receiving financial incentives.

**Study design**
PARACAO was the first intervention to deliver HPV-based cervical screening under routine conditions before potential dissemination throughout the country. To better understand the interplay between PARACAO effectiveness and its implementation, we designed a pragmatic hybrid-effectiveness implementation Type III study [16] using mixed methods [17, 18]. Therefore, we focused primarily on PARACAO effectiveness and secondarily on the process evaluation of its implementation. The latter evaluation was performed according to Medical Research Council (MRC) guidelines [19]. Following a baseline of formative research and using consultations with main stakeholders and researchers (see Additional file 1: Table S4), we defined a theory of change [20] (ToC, Fig. 1) that depicts the various components

| Table 1 | Healthcare facility characteristics |
|---------|-----------------------------------|
|          | Center A       | Center B       |
| Physician| 1              | 2              |
| Midwives/nurses | 12             | 9              |
| Birth attendants | 11             | 14             |
| Laboratory staff | 4 technical staff, 1 head | 2 technical staff, 1 head |
| Daily prevention consultation | 115            | 90             |
| Daily curative consultation | 130            | 100            |
| Annual target population (25–55 years) for cervical screening | 3630           | 2415           |


Table 2 Components of the PARACAO implementation strategy, underlying theories and assumptions

| Component                  | Description                                                                 | Theory                                                      | Assumption                                                                 |
|----------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------|
| Integration of healthcare services | Through the process of implementation, healthcare providers and implementers decide on modifications to existing systems, structures, or tasks to offer women the possibility of having an HPV test at the primary healthcare center | Continuum of care for sexual and reproductive health services [11–13] | Integrating HPV testing within primary care enhances both cervical cancer screening and sexual/reproductive health services uptake |
| Education of healthcare providers | Off-site training of healthcare providers to update their knowledge, persuade them to change their practices, and maintain their competence | Cognitive and learning theories [14] | Education favors the integration of new practices in healthcare settings and improves the quality of cervical cancer screening |
| Outreach educational visits | A trained supervisor visits each target provider at participating facilities to explore problems, identify possible local solutions, and discuss their concerns | Health promotion, innovation, and social marketing theories [15] | Regular supervisory visits to healthcare providers to help maintain their skills and performance |
| Patient counseling | Midwives deliver counseling to women at various steps of the screening process: before HPV testing, after the results, after triage and after appropriate treatment if relevant | Women empowerment [16] | Counseling by a trained midwife benefits woman by facilitating a process of informed participation in the context of improved knowledge |

Fig. 1 Theory of change (ToC). ToC depicts the various components of the implementation, the assumed pathways through which these components could bring about the targeted changes (mechanisms of change) and the underlying hypotheses that need to hold true for that changes to occur. Indicators are collected at the facility level (weekly reports and monitoring reports) and individual level (cohort study).
of the implementation strategy, the assumed pathways through which these components could bring the targeted changes (mechanisms of change) and the underlying hypotheses that need to hold true for those changes to occur.

Based on this ToC, we considered three subcategories of indicators for the process evaluation: fidelity, whether the intervention was delivered as intended; reach, whether women came into contact with the screening offer and appropriate services if needed; and dose, the quantity of intervention implemented. We also assessed whether adaptations of the intervention were required to fit the context of the participating centers and make it more acceptable to women and healthcare providers. The study was conducted from July to December 2019 using a concurrent parallel quantitatively driven mixed-method design [18] (see Fig. 2) that consisted of a cohort study, routine data use, direct observations and semistructured interviews.

Sampling, data sources and collection
Table 3 outlines the data sources, participants, methods used and outcomes.

Quantitative data
Cohort study Women were recruited while attending one of the participating facilities for CC screening and were followed up until completion of the screening sequence. The inclusion and exclusion criteria in the cohort were similar to those considered for screening eligibility.

Data were collected through questionnaires at each step of the screening sequence: after women returned their sample to the laboratory, after they received their HPV test result and after they underwent VIA and treatment if needed. When women did not return to the healthcare center over the 30 days following the sampling, they were contacted by phone.

The questionnaires collected demographic information (age, screening history, living area, and socioeconomic level), CC literacy, intervention delivery data (choice of the sampling method, understanding of test results and recommendations (see Additional file 1: Table S2), date and time for testing, result and postresult management, triage and treatment), and satisfaction at each step of the screening sequence. Socioeconomic (SES) levels were calculated using a wealth index (see Additional file 1: Table S3) according to the asset method [21] and divided into terciles. Participant cervical cancer literacy was assessed after cervical specimen collection using the CC Literacy Assessment Tool (C-CLAT), a 16-item instrument that has been validated in various contexts [22–24]. Each item of the C-CLAT was scored as binary (0 = incorrect, 1 = correct), and the total score computed as the sum of individual items ranged from 0 to 16, with higher scores indicating higher literacy.

Weekly supervision report Weekly supervision reports regarding the participating facilities were compiled for the first implementation semester. Weekly supervision reports were retrieved from the project monitoring and evaluation weekly reports starting from the project conception (2018) to the end of the first implementation semester. An in-depth search was made by looking for data related to the implementation process and indicators.

Facility routine health information system Each participating facility has a health information system that collects routine data. We retrieved data derived from two registries: CC screening process (clinical data) and HPV testing (laboratory data) for the first implementation semester. Collected clinical data consisted of women's screening history and description of screening steps (date and time, sampling method, HPV results, VIA results, treatment performed and referral when needed). Laboratory data consisted of day and time for sampling reception, sampling validity, HPV results and genotyping, and time and date for results transferred to midwives.

Qualitative data
Direct observations Direct observations were performed at each participating facility. The anthropologist performed participant observations during the first 2 months of the project implementation. He repeatedly observed various screening activities that took place in the waiting room, in the cervical screening room (sampling performance, the results communication, VIA triage and treatment) and in the laboratory room until saturation was obtained. Realized at various times of the day and of the week over 2 months, the observations covered 90 medical visits and 30 laboratory procedures.

Semistructured in-depth interviews Maximum variation sampling was used to achieve a diverse sample of providers of various qualifications, sexes and seniorities (n = 08 per facility) for individual in-depth interviews. The same method was used to obtain a diverse sample of 20 women in terms of age, religion, ethnicity, and HPV status (n = 10 per facility).

The anthropologist conducted semistructured in-depth interviews with the women in their language (Dioula or Mooré) and recorded them between September and December 2019. Women were contacted 2 months after their involvement in the screening process and met outside the facilities. The interviewed women received transportation fee reimbursement as compensation for their time. Semistructured in-depth interviews conducted in French with healthcare providers were performed during
their working time and were recorded. All interviews were conducted throughout the implementation stage.

**Outcomes**

*Effectiveness outcome* The primary outcome was participant screening completeness. A screening sequence was considered complete in each of the following cases: (1) when an HPV-negative woman was informed of the result of her HPV test, (2) when an HPV-positive woman had a subsequent negative VIA test, or (3) when an HPV-positive woman with a subsequent positive VIA test received appropriate treatment.

The secondary outcome was satisfaction with the screening proposed, measured at each step of the screening sequence—postsampling, postresult and post-VIA if applicable. Assessment was realized through a 3-point Likert scale—fully agree, agree, disagree—exploring four dimensions: willingness to repeat the screening; satisfaction regarding the explanation delivered; satisfaction regarding the intervention delivered (sampling performance, VIA and treatment); and willingness to encourage close friends to participate in the same screening procedure.

*Process evaluation* All indicators are listed in Fig. 1.

**Fidelity** The included individual measures of fidelity were derived from the cohort study and were related to the completion of the different steps of the screening and facility-based measures of fidelity that arose from the weekly supervision reports. Fidelity was considered optimal when the elements listed above were successfully completed and the expected rate was 100%.

*Reach* Reach was measured at the facility level and was defined by the daily number of women screened per center. We assumed 20 working days per month with a level of desired achievement set at 4 women screened per day and per center. Data were extracted from the facilities’ routine health information systems.

*Dose* Indicators of dose were assessed at the individual level using data from the cohort study.

**Qualitative data**

*Women's experience* We explored women’s knowledge on CC, their motivation to undergo screening and their experience with HPV-based screening.

*Healthcare workers’ experience* We explored healthcare workers’ experience with the implementation, their relationships with implementers, adaptations made
Table 3  Data sources, participants and outcomes

| Method                          | Participants/recruitment                                                                 | Sampling                                                                 | Data collection timing          | Outcomes                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------|--------------------------------------------------------------------------|
| **QUANTITATIVE DATA**          |                                                                                         |                                                                          |                                |                                                                          |
| Weekly supervision report      | Women included in the cohort study, healthcare workers involved in the screening process at participating facilities | Facilities included in the implementation process                       | January 2018 to December 2019 | Implementation outcome Facility-based measure of fidelity                |
| Facility routine health information system | Women included in the cohort study, healthcare workers involved in the screening process at participating facilities | Registries, CC screening process (clinical data), HPV testing (laboratory data) | May to December 2019           | Reach—Number of women screened daily Dose—Screening process time, screening steps |
| Questionnaires (cohort study)  | 300 women (150/facility) attending facilities for CC screening and eligible for screening as defined by the project | Sample size calculated to provide a 5% accuracy in the measurement of screening completeness Based on an expected screening completeness of 80% and to protect against refusal to participate and dropouts, we decided to include 300 women (n = 150 per facility) | July 1st to October 31st, 2019 | Effectiveness outcomes Screening completeness Screening process satisfaction: post-sampling, postresult and post-VIA if applicable Implementation outcomes Individual measure of fidelity Screening steps Context Women’s characteristics |
| **QUALITATIVE DATA**           |                                                                                         |                                                                          |                                |                                                                          |
| Observations                   | Women attending facilities for CC screening, healthcare workers involved in the screening process (90 medical visits, 30 laboratory procedures) | Screening activities at facilities Waiting room Screening room Laboratories | July 1st to August 31st, 2019 | CC screening practice Adaptation performed by healthcare workers          |
| Semistructured interviews      | 20 Women included in the cohort study, 20 healthcare workers involved in the CC screening process | Maximum variation sampling was used to achieve a diverse sample of providers of various qualifications, sexes and seniorities (n = 08 per facility) for individual in-depth interviews. The same method was used to obtain a diverse sample of 20 women in terms of age, religion, ethnicity, and HPV status (n = 10 per facility) | September 1st to November 20th, 2019 | Women’s CC knowledge, Motivation to undergo screening Experience with HPV-based screening Healthcare workers’ reasons for program adaptation |
throughout the first stage of implementation and the reasons for deviation from the intervention protocol.

**Data analysis**

Quantitative and qualitative analyses were performed independently, and the results were triangulated to look for similarities and discordances. Quantitative data were analyzed using R software version 3.6.3, and qualitative data were analyzed using NVivo software version 12.6.0.

**Quantitative data analysis**

**Screening effectiveness and implementation** Data were described using counts and proportions for categorical data, means and standard deviations or medians and interquartile ranges (IQRs) for continuous data. The primary outcome was measured as the proportion of women with a complete screening sequence among screened women. The secondary outcome was measured as the proportion of women highly satisfied, i.e., answering "fully agree" to all of the satisfaction dimensions.

**Effects of implementation variability on effectiveness outcomes** We performed three multivariate logistic regression models to test the association between effectiveness outcomes (screening completeness, postsampling and postresult satisfaction) and individual measures of fidelity and dose. As screening completeness was by definition achieved when a single visit occurred, we performed a subgroup analysis focusing on women who had a multiple-visit approach. Implementation indicators that were considered nondiscriminant (i.e., variables with more than 95% or less than 5% frequency) were not included in the models. When collinearity among variables was detected, only one indicator was selected. The variables were eventually included in the multivariate logistic regression model if they were significantly associated with the outcome in bivariate analysis using a cutoff point of $p < 0.20$. Each model was adjusted for the health center and demographic information (age, screening history, socioeconomic level, travel cost and literacy score). The associations between post-VIA satisfaction or posttreatment satisfaction and implementation variables were not explored due to the limited group sizes ($n = 55$ and $n = 5$).

Comparison of implementation variables and effectiveness outcomes between centers was performed using the chi-square test for binary variables and Student’s $t$-test or the mood test for continuous variables. The association between demographics and effectiveness outcomes was also analyzed using multivariate logistic regression adjusted for the health center.

**Qualitative data analysis** Direct observation notes were transcribed and compiled through an observation report. All recorded interviews were transcribed and, if necessary, translated in French by the initial interviewer. Reports, transcribed interviews and administrative reports were imported into NVivo software. An inductive analysis of observations and each interview was performed that led to major theme extraction as defined in the thematic analysis approach [25]. After being grouped into a scheme reflecting the implementation process, findings from observations and interviews were triangulated with relevant literature and discussed with a panel of experienced anthropologists.

**Ethical considerations**

The study received full ethical approval from the Ethics Committee of Health Research of Burkina Faso (n° 2019-5-064). All women received an information note and signed a consent form before inclusion in the cohort study. Informed consent was obtained from all participants.

**Results**

**Quantitative findings**

Between July 1st and September 30th, 2019, 350 women attended CC screening services, of which 317 (90%) were eligible for HPV-based screening and eventually included in the cohort study (Fig. 3). Table 4 presents the demographics of the screened women. The majority of them were aged between 25 and 35 years old (61.4%), lived in Ouagadougou (97%) and had no previous screening history (65.3%), with no difference between study sites. Despite the wealthiest women attending Center B and the poorest women attending Center A (p < 0.001), the CC literacy level was similar between centers with a median score of 10/16.

**Screening completeness** Among the 317 screened women, 299 (94%) had a complete screening sequence (Fig. 3 and Table 5). The more screening steps that were needed, the lower the screening completeness achieved. Of the 68 women (21.4%) who tested HPV positive, 55 (80.8%) had a VIA triage test, and of the 6 HPV+ VIA + participants, only 3 were treated. Screening completeness did not differ between centers (Table 5).

**Women's satisfaction** The proportions of women highly satisfied varied across the screening steps. The highest satisfaction scores were observed after disclosure of the HPV test results (94.6% of women highly satisfied). Postsampling satisfaction was significantly lower in Center B than in Center A, while it was the opposite for post-HPV test result satisfaction (Table 5).

**Fidelity** All implementation activities at the facility level in terms of equipment, structure, staff training, supervision and referral system to ensure an optimal environment for HPV-based screening were successfully completed (Fig. 4A). All screened women were counseled...
by midwives before screening and were exempted from fees (see Additional file 1: Table S5). Midwives offered a choice of sampling method in 72.5% of cases (57.5% in Center A vs 87.9% in Center B, \( p < 0.001 \)). Only 27.4% of women benefited from a single visit, with no difference between centers (27.5% in center A vs 27.3% in Center B, \( p = 0.98 \)).

**Reach** In Center A, the trend of daily screened women was uneven, with a peak in July followed by a decrease in August and December (Fig. 4B). In Center B, the screening rate was lower but constantly increased from May to December. In both centers, the reach indicator stabilized at approximately four screened women per day after a 3-month implementation period.

**Dose** The average time to submit samples to a laboratory was 1.22 h (SD = 0.88) and was twice as high in Center B than in Center A (see Additional file 1: Table S6). Overall, the HPV test was performed using self-sampling in 67.5% of cases, with fewer performed in Center B (50%) than in Center A (85%), \( p < 0.001 \). The average time between specimen sampling and results disclosure was 2.7 days (SD = 4.01), with no statistically significant difference between centers. A total of 92.4% of women correctly understood their HPV results, and 74.4% of them correctly understood the recommendations made by the midwives for postresult management. The understanding of the results and recommendations was similar in both centers.

**Fig. 3** Cohort study data flow. Colored cells indicate WHO guidelines. * indicates the cohort study endpoints.
Effect of implementation on effectiveness

Having been screened in a single visit and the time to return samples to the laboratory were not associated with screening completeness ($p = 0.43$ and $p = 0.67$, respectively) in the bivariate analysis. In the multivariate analysis (see Additional file 1: Table S7), screening completeness was positively associated with having performed a self-sampling (adjusted odds ratio (ORa) = 4.18; 95% confidence interval (CI) [1.09–17.72]) and having a good understanding of the test results (ORa = 10.62 95% CI [2.10–63.04]). The same factors were found when the analysis was restricted to women who did not benefit

### Table 4  Participant demographics

|                                      | All centers (N = 317) | Center A (N = 160) | Center B (N = 157) | p value |
|--------------------------------------|-----------------------|--------------------|--------------------|---------|
| **Age in years (%)**                 |                       |                    |                    |         |
| 25–35 years old                      | 153 (48.3)            | 78 (48.8)          | 75 (47.8)          | 0.985   |
| 36–45 years old                      | 142 (44.8)            | 71 (44.4)          | 71 (45.2)          |         |
| 46–55 years old                      | 22 (6.9)              | 11 (6.9)           | 11 (7.0)           |         |
| **Living area (%)**                  |                       |                    |                    |         |
| Ouagadougou                           | 295 (97.0)            | 149 (95.5)         | 146 (98.6)         | 0.207   |
| Outside Ouagadougou                   | 9 (3.0)               | 7 (4.5)            | 2 (1.4)            |         |
| Unknown                               | 14 (4.4)              | 5 (3.1)            | 9 (5.7)            |         |
| **SES level (%)**                    |                       |                    |                    | <0.001  |
| High                                 | 111 (35.0)            | 47 (29.4)          | 64 (40.8)          |         |
| Intermediate                         | 162 (51.1)            | 79 (49.4)          | 83 (52.9)          |         |
| Low                                  | 44 (13.9)             | 34 (21.2)          | 10 (6.4)           |         |
| **Screening history (%)**            |                       |                    |                    | 0.115   |
| At least once                        | 97 (30.6)             | 42 (26.2)          | 55 (35.0)          |         |
| Never                                | 220 (69.4)            | 118 (73.8)         | 102 (65)           |         |
| **Travel cost for screening process (%)** |                     |                    |                    | 0.095   |
| None                                 | 59 (18.6)             | 33 (20.6)          | 26 (16.6)          |         |
| Low                                  | 67 (21.1)             | 38 (23.8)          | 29 (18.3)          |         |
| Intermediate                         | 106 (33.4)            | 43 (26.9)          | 63 (40.1)          |         |
| High                                 | 85 (26.8)             | 46 (28.7)          | 39 (24.8)          |         |
| **Literacy score (median (IQR))**    |                       |                    |                    | 0.692   |

* Travel cost is the average amount of money spent by women traveling to healthcare centers during the screening process. It could be none (0$), low ($\leq 0.90$), intermediate ($\leq 1.80$ or high ($> 1.80$). All cost are in US dollars

### Table 5  Primary and secondary outcomes

|                                      | Overall                  | Center A                | Center B                | p value  |
|--------------------------------------|--------------------------|-------------------------|-------------------------|----------|
| **Screening completeness**            |                          |                         |                         |          |
| HPV-negative women, the results given| 247/249 (99.2)           | 127/128 (99.2)          | 120/121 (99.2)          | 1        |
| HPV-positive women, VIA done and negative | 49/55 (89.1)          | 21/25 (84.0)            | 28/30 (93.3)            | 0.56     |
| HPV-positive women, VIA positive and treatment provided | 3/6 (50.0)          | 2/4 (50.0)              | 1/2 (50.0)              | 1        |
| Women with complete screening sequencea | 299/317 (94.3)         | 150/160 (93.8)          | 149/157 (94.9)          | 0.84     |
| **Women satisfaction (high vs low)b**|                          |                         |                         | <0.001   |
| Postsampling                         | 205/317 (64.7)           | 128/160 (80.0)          | 77/157 (49.0)           |          |
| Postresults                          | 300/315 (94.6)           | 146/158 (91.2)          | 154/157 (98.1)          | 0.014    |
| Post-VIA                             | 38/55 (69.1)             | 15/25 (60.0)            | 23/30 (76.7)            | 0.29     |

Data are number of women (%)

* Screening sequence was considered complete when an HPV-negative woman was informed of the result of the HPV test, when an HPV-positive woman had a subsequent negative VIA test, or when an HPV-positive woman with a subsequent positive VIA test had an appropriate treatment

b Satisfaction was assessed at three steps: after vaginal sampling (postsampling); after women received their test results (postresults); and after the visual inspection if relevant (post-VIA)
from a single visit (see Additional file 1: Table S7), along-side a higher odds of not completing the screening process when the time until result disclosure increased (ORa = 0.16, 95% CI [0.02–0.89]).

Postsampling satisfaction was not associated with any of the dose indicators (see Additional file 1: Table S8). Postresult satisfaction was negatively associated with the level of understanding of the results (ORa = 0.06 95% CI [0.01–0.23]) (see Additional file 1: Table S8). Postresult satisfaction was higher when women received their results within 24–48 h instead of the same day (ORa = 7.03 95% CI [1.40–54.79]).

Role of demographic characteristics Demographic characteristics were not associated with screening completeness (see Additional file 1: Table S9). However, postsampling satisfaction decreased among women aged 36–45 compared to that among women aged 25–35 (ORa = 0.52 95% CI [0.30–0.88]). In addition, the adjusted odds of being highly satisfied was almost two times higher among women with a screening history than among women without a screening history (ORa = 1.97 95% CI [1.10–3.63]). Postresult satisfaction was positively associated with the amount of money spent on travel (see Additional file 1: Table S9).

Effects of context on implementation outcomes A difference between the reach of the centers was observed at the beginning of the implementation, and these differences can be explained by a “launching effect”. Indeed, the official start of the PARACAO was announced on TV and in newspapers, and despite the announcements indicating that two centers would be involved, the campaign was more focused on one of the two centers.

Likewise, the differences in dose and fidelity found between centers could be explained by differences in internal organization. One center had a dedicated midwife for screening, which resulted in no need for task

---

**Fig. 4** Implementation strategy fidelity and reach. A Implementation component fidelity. Level of achievement (%) of the various components of the implementation strategy overall (blue) and by center. The expected level of achievement indicated by the dashed red line. Material-oriented actions received a high level of achievement (equipment and training). B Daily screening activity. The reach outcomes are presented as the expected daily number of eligible women screened per center (dashed line) and in all centers (dotted line) according to the initial plan. The overall variations are shown in blue, the variations from Center A are shown in green, and those from Center B are shown in red.
shifting while she was performing screening. That was not the case in the other center.

In addition, despite having similar populations in their service areas, the two centers had different staffing and activity capacities (Table 2), which could also explain the differences found in effectiveness and implementation outcomes.

Qualitative findings

Adaptation The main adaptation that was implemented to make the PARACAO fit different contexts involves the “screen-and-treat” approach. In one center, HPV test results could be given on the same day as the sampling, but if VIA was needed, the women had to return another day. In the other center, women were systematically asked to return the next day to obtain their test results. In both centers, laboratory staff adapted the initial plan by setting closing times for sample collection that matched their own organizational schedules. The closing times were 10:00 am in one center and 11:00 am in the other, which allowed laboratory staff to perform other routine tests without affecting their working hours (7:00 am to 4:00 pm). Finally, women self-selected themselves and did not come after a certain time of the day, as they knew that screening would no longer be available (see Additional file 1: Table S10).

The counseling was also adapted to improve women’s understanding as perceived by the caregivers. Indeed, health workers expressed concerns regarding the communication of screening results: “How do we explain HPV-positive results in the local language?” (Healthcare provider, 12 years of experience). To circumvent these language difficulties, the counseling was often adapted without using either HPV or CC vocabulary: “It’s ok, you have nothing” was a sentence commonly used.

Healthcare worker’s satisfaction During interviews, the healthcare workers praised the capacity strengthening offered by the training during the implementation process. Indeed, few had received formal training for VIA, and they gained knowledge and self-confidence through the training: “It helps us to work with more confidence [...] now we know the difference when we see the cervix. In terms of knowledge, it really gave us something” (midwife, 8 years of experience). Likewise, the laboratory staff considered that they were trained for more than HPV testing: “It’s a plus for us, because you can test many other things than just HPV with this platform. You just have to change the cartridge and the software, and you can test TB, hepatitis B...” (laboratory staff, 25 years of experience). However, all of them pointed out the additional workload due to the HPV screening strategy as expressed by a midwife “before it was simple, now we have to take time to explain, explain again before doing the test, and it takes much more time” (midwife, 8 years of experience) and suggested some solutions, such as “we said to the NGO that maybe it would be better to group women and screen them once a week [...]” (laboratory staff, 7 years of experience).

Women’s satisfaction Patient interviews showed that women were motivated by their peers to obtain screening: “A colleague of mine, she did the test and she told me that I should do it, it’s free” (woman, 29 years old, high school education). This was particularly the case since the PARACAO was perceived as “a novelty brought by white people, so it has better quality than the old method (VIA test)” (woman 34 years old in the waiting room, previously screened, primary school education). However, they often expressed their disappointment about the counseling quality when asked about their screening experience: “the explanations the midwife gave me were... not good. She didn’t explain to me anything about the cancer before the test. When I came back for the results, she explained, but just a little bit.” (woman 30 years old, college education, never screened). This disappointment was higher among women who had heard of the screening procedure from peers: “My cowives told me that they explain the cancer causes and give advice. [...] but when I came, nothing like this happened” (woman 33 years old, never screened, primary school education, right after her screening). Furthermore, the choice offered for sampling collection raised mixed feelings among women and may have affected satisfaction. Some participants believed that the healthcare providers should have decided instead of them, while others were happy with the opportunity offered. From interviews, it appeared that the women with the highest level of education and prior awareness of the screening novelty were more likely to choose self-sampling, as it respected their intimacy: “I appreciated it [the self-sampling] more, because with the old version and the speculum, it hurts. This time, I didn’t feel anything. And I didn’t have to lay down, it was good.” (woman, 26 years old, previous screening, college education). Women without prior knowledge and with a lower level of education relied more on caregivers: “I think that if the midwife does the sampling it’s better [...] I trust them more, it’s their job, not mine” (woman 33 years old, never screened, no education).

Discussion

This study provides insight into the implementation process of an HPV-based cervical cancer screening program (Fig. 5), which is important for the future expansion of HPV-based screening of CC as envisioned by the WHO [26]. We found that the healthcare providers of both facilities adhered relatively well to the various components of the screening implementation and accepted
integrating HPV screening into their work schedules. However, they had to adapt the strategy by moving from a “screen-and-treat” approach to a multiple-visit approach. This adaptation was the result of a dialogue between midwives and laboratory staff in both centers to facilitate the integration of screening activities into the existing work structure, revealing a context modification according to Stirman’s classification [27]. As observed in other contexts, this type of adaptation to fit an organization could enhance sustainability [28, 29].

Despite the modifications, both facilities nearly achieved the level of desired screening activity (4 women screened per day), and although women rarely received results on the same day that they provided the samples, 94% of them had a complete screening sequence. These findings mitigate the usual paradigm whereby multiple visits result in a high dropout rate among women [30, 31].

Through this analysis, we identified aspects of the implementation process critical to screening completeness and satisfaction. The main determinant for screening completeness was the understanding of the results by the women. This result is linked to the poor counseling quality as expressed by the women. The importance of counseling content on screening uptake, treatment adherence and health behavior has been demonstrated for other health conditions [32, 33], and evidence indicates that it is more important than counseling duration [34]. In our study, midwives complained about the lack of adequate words in the local language for delivering the correct message. This issue could be resolved by adapting messages to the local language with the help of social scientists or linguists. Indeed, the literature shows that effective health communication requires both cultural and language adaptations [35, 36]. Self-sampling, whether chosen or not, was also found to be associated with screening completeness. This method prevents women from undergoing a gynecological examination during the first screening step and thus diminishes the embarrassment associated with this examination, which is one of the main barriers to cervical screening [37–39]. In addition, self-sampling as an empowering tool [40] may have played a role in this high completion rate. Other hypotheses could be raised to explain the high completion rate. First, many women were interested in this new screening strategy, as it was imported by westerners, which was perceived as a “guarantee of quality”, leading to reduced dropouts due low-quality health services [41, 42]. A similar situation was found by Doctors Without Borders in Niger, where NGOs targeting health issues were positively perceived by the population [43]. DOTW is an NGO known for its work with communities, which may explain why women were more prone to participate and return to the health center when contacted by DOTW [44].
Moreover, the program was implemented in an urban area within a major city, where constraints associated with healthcare access—road conditions, field work, distance—are less important [38, 45], which could also explain this high completion rate [37].

Of note, we found that women living farther from the participating facilities were more likely to be satisfied. This counter-intuitive result could be explained by the fact that these women were attracted by the novelty of the screening and were unfamiliar with the center, and hence had different expectations from those living in the immediate vicinity of the center.

We found that screening completeness and patient satisfaction were higher for a rapid two-step approach (within 48 h) than for a single-visit approach. This suggests that cumulative wait time at the healthcare center may hinder screening satisfaction and that the two-step strategy might better fit in this context. Observations and interviews in healthcare centers revealed that wait times were related to health service organization and staffing. This raises questions about the potential effect of adding new services or, more generally, integrating new services into saturated centers. Studies report conflicting results, with some showing that integration may improve service use without changing health outcomes due to imposing additional workloads [46] and others showing that integration has positive long-term effects [47]. Although further research is needed to clarify the effect of CC screening integration [48], our findings highlight the implementation components that are essential to providing HPV-based screening at the primary-care level [49]. If the single-visit screen-and-treat approach is to be prioritized in a future national strategy, important changes to staffing or in work structure will be required. Either more lab technicians will be needed, which seems quite unlikely with the current limited health budget; midwives will need to be allowed to perform HPV testing, which could facilitate a one-step approach [50]; or reliable point-of-care HPV testing that does not require a traditional laboratory setting must be developed [51]. Such alternatives need to be further explored.

Some limitations to our results are worth noting. First, the assessment encapsulated the early stages of implementation and may not capture all aspects of the project in terms of reach, dose and fidelity. However, we believe that early adaptations are of central importance and will shape the final form of the project. Furthermore, observations performed during this first stage may have modified healthcare workers’ behavior (Hawthorne effect). However, we tried to mitigate this effect through the observation process itself (establishing rapport, long-time observation) and later through a triangulation between all qualitative and quantitative data. Similarly, we may have encountered a recall bias regarding women’s screening experience as interviews were performed 2 months after the screening started. This could have led to overestimation of extreme experiences (positive or negative). However, findings from interviews were convergent with findings from the cohort study, which suggests that this bias may have been reduced. Our study was limited to two centers, which makes generalization of our findings difficult. We tried to overcome this issue through our cohort study sample size and maximum variation during interviews with women to reflect various screening situations. In addition, the study sites were located in urban areas without access restrictions. Maintaining a single visit for the screen-and-treat approach may turn out to be more important in such settings, but more research is necessary to confirm this. Another limitation that should be acknowledged is the absence of information on the outcomes of the women who were referred for cancer or large treatment management.

Policy implications Our results highlight that further research is needed to grasp the potential success of HPV implementation in rural settings (Fig. 5). However, we have demonstrated that some gaps could be filled in the near future to drive HPV-based screening in urban settings. First, offering formal systematized counseling at each step would improve women’s understanding while reducing healthcare workers’ wording issues. Then, an individual facility preparedness assessment needs to be performed before implementation to account for the existing workload and healthcare workers’ needs in terms of adaptation. Additionally, as a multiple-visit approach will probably be used, establishing a pragmatic follow-up strategy through community health workers and accurate registries would help in reducing this risk. Finally, a guarantee for free-of-charge CC screening is one of the most important steps to promote successful implementation.

Conclusion Despite some limitations, we believe that our results have important implications for future programs and healthcare providers in low-resource settings, especially in the context of expanding HPV-based screening strategies at the primary-care level.

First, the single-visit approach should not be the ultimate goal for HPV-based cervical screening, and the multiple-visit approach is an acceptable option in the urban context as long as results are given within 48 h and adequate counseling is provided. Baseline assessment is needed to adapt the intervention to workload and staffing constraints to reduce the wait times for testing and result disclosure as much as possible. Efforts should be made to involve patients in deciding their sampling collection.
method and to counsel them with appropriate language and wording. These results will help decision-makers design effective future HPV-based screening implementations in resource-constrained settings.

Abbreviations
CC: Cervical cancer; CI: Confidence interval; DOTW: Doctors of the World; FP: Focal point; HPV: Human papilloma virus; IARC: International Agency for Research on Cancer; LEEP: Loop electrosurgical excision; LMICs: Low- and middle-income countries; MRC: Medical Research Council; NGO: Nongovernmental organization; ORa: Adjusted odds ratio; PARACAO: Partnership for Action and Research against Cervical Cancer in West Africa; VIA: Visual inspection with acetic acid; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12905-021-01392-4.

Additional file 1. Supplementary material relative to methods applied and results presented in the main manuscript

Acknowledgements
We thank all the participants of our study: the women who agreed to participate and spent their time with us; the caregivers who allowed us to observe and collect data from them; our research assistants—Fatoumata KARAMBI, Daraja KORASSOUM, Dorothée GUIRYENGAR, Salimata SALAMAMBÉRE and Alice TIENDREBEOGOO— for cleaning and managing the data; the local DOTW team based in Ouagadougou who hosted us and implemented the project, especially Dr. Linda TRAORÉ, and the lead DOTW team that supported us throughout the study. We also thank Sidacité for funding our research through the Young researcher grant.

Authors’ contributions
KM, PDB, AD, DP and VD designed the study. KM and CK were responsible for coordinating the study and data acquisition. SZ collected and analyzed the qualitative data. KM, AD and PDB analyzed the data, and all authors (KM, AD, PDB, MB, CK, SZ, VD, and DP) were involved in the data interpretation. KM, AD and PDB drafted the main manuscript, and all the authors (KM, AD, PDB, MB, CK, SZ, VD, and DP) added intellectual content and revised the paper. All authors read and approved the final manuscript.

Funding
The funders (Fondation de Médecins du Monde and Sidaction) had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript (Grant No. Young Researcher Award #12218).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Informed consent was obtained from all participants. All women included in the study received an information note and signed a consent form before data collection. Other participants gave their informed consent before being interviewed. All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). The study received full ethical approval from the Ethics Committee of Health Research of Burkina Faso (n° 2019-5-064).

Consent for publication
Not applicable.

Competing interests
The authors declare no financial and nonfinancial conflicts of interest.

Author details
1Centre Population et Développement (Ceped), Inserm ERL 1244, UMR Institut de recherche pour le développement (IRD) et Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France. 2Institut de Recherche en Sciences de La Santé (IRSS), Ouagadougou, Burkina Faso. 3Laboratoire de Recherche Interdisciplinaire en Sciences sociales et Santé (LARISS), Université Ouaga 1, Ouagadougou, Burkina Faso. 4Pôle Recherche et Apprentissages, Médecins du Monde, Paris, France.

Received: 20 January 2021 Accepted: 11 June 2021

Published online: 23 June 2021

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. WHO | WHO leads the way towards the elimination of cervical cancer as a public health concern. WHO. World Health Organization; [cited 2020 Jun 12]. http://www.who.int/reproductivehealth/cervical-cancer-public-health-concern/en/.
3. Gustafsson L, Pontén J, Zack M, Adami H-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755–63.
4. Ajenifuja KO, Gage JC, Adepiti AC, Wentzensen N, Eklund C, Reilly M, et al. A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria. Int J Gynecol Cancer. 2013;23:507–12.
5. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, et al. ATL. Int J Gynecol Cancer. 2014;24:576–85.
6. Sankararanayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385–94.
7. Denny L, Kuhn L, Hu C-C, Tsai W-Y, Wright TC. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. JNCI. 2010;102:1557–67.
8. BurkinaFaso_2013 STEPS_Report.pdf. [cited 2020 Jun 12]. https://www.who.int/countries/buf/steeps/burkinafaso_2013 STEPS_Report.pdf.
9. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107.
10. Sawadogo B, Sheba GN, Rutebemberwa E, Sawadogo M, Meda N. Knowledge and beliefs on cervical cancer and practices on cervical cancer screening among women aged 20 to 50 years in Ouagadougou, Burkina Faso, 2012: a cross-sectional study. Pan African Medical Journal. 2014 [cited 2020 Jun 17]. http://www.panafrican-med-journal.com/content/article/18/175/full/.
11. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases Report - AFRICA. 2018 Dec. https://hpvcentre.net/statistics/reports/XFR/pdf?1=1557137282254.
12. Cosse MH. La carte sanitaire à l’épreuve des pratiques sanitaires des citadins: Analyse des aires d’attraction des structures de soins à Ouagadougou (Burkina Faso). TEM. 2007;34–46.
13. Equipe PARACAO. Etude socio-ethnographique des facteurs influençant l’accès à la prévention et aux soins du cancer du col de l’utérus à Ouagadougou, Burkina Faso. Rapport de recherche, Ceped, Médecins du Monde; 2019.
14. World Health Organization, editor. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization; 2013.
15. Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Practical considerations. Xpert MTB/RIF Implementation Manual: Technical and Operational How-To; Practical Considerations. World Health Organization, 2014 [cited 2020 Jun 26]. http://www.ncbi.nlm.nih.gov/books/NBK254529/.
16. Curran GM, Bauer M, Mittman B, Pyne JM, Steitel C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness.
21. Howe LD, Hargreaves JR, Huttly SR. Issues in the construction of wealth indices for the measurement of socio-economic position in low-income countries. Emerging Themes in Epidemiology. 2006 [cited 2020 Apr 9];S. https://ete-online.biomedcentral.com/articles/10.1186/1745-6215-15-267.

22. Williams KP, Templin TN. Bringing the real world to psychometric evaluation of cervical cancer literacy assessments with Black, Latina, and Arab Women in Real-World Settings. J Cancer Educ. 2013;28:738–43.

23. Talley CH, Williams KP. Impact of age and comorbidity on cervical and breast cancer literacy of African Americans, Latinas, and Arab Women. Nurs Clin North Am. 2015;50:545–63.

24. Rivera-Vasquez O, Mabaso A, Hammad A, Williams KP. A community-based approach to translating and testing cancer literacy assessment tools. J Cancer Educ. 2009;24:319–25.

25. Qualitative research practice: a guide for social science students and researchers. Choice Reviews Online. 2005;41:41–1319–41–1319.

26. WHO | WHO Director-General calls for all countries to take action to support global cervical cancer screening. May 2020 [cited 2020 Apr 15];15. https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-267.

27. Wittsay Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting adaptations and modifications to evidence-based interventions. Implementation Science. 2019 [cited 2020 Nov 3];14. https://publications.ginnier.cn/doi/10.1186/s13012-019-0988-y.

28. Iwelunmor J, Blackstone S, Veira D, Nwaouzuru U, Airihenbuva C, Munodawafa D, et al. Toward the sustainability of health interventions implemented in sub-Saharan Africa: a systematic review and conceptual framework. Implement Sci. 2016 [cited 2018 Dec 5];11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804528/.

29. Hailemariam M, Bustos T, Montgomery B, Barajas R, Evans LB, Drahot A. Evidence-based intervention sustainability strategies: a systematic review. Implementation Science. 2019 [cited 2020 Jun 18];14. https://implementationscience.biomedcentral.com/articles/10.1186/s13012-019-0910-6.

30. Jeromino J, Morales Q, Homa J, Pariona J, Marinque J, Rubiños J, et al. Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings. Revista Panamericana de Salud Pública. 2005 [cited 2020 Oct 5];17. http://www.scielo.org/scielo.php?script=sci_arttext&pid=S1020-49922005000100001&lng=en&nrm=iso&tlng=en.

31. Catarino R, Vassilakos P, Tebeu P-M, Schaffer S, Bongoe A, Petignat P. Genetic factors associated with human papillomavirus prevalence and cervical neoplasia among Cameroonian women. Cancer Epidemiol. 2016;40:60–6.

32. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database of Systematic Reviews. 2017 [cited 2020 Aug 6]. https://doi.wiley.com/10.1002/14651858.CD000122.pub3.

33. Fonner VA, Denison J, Kennedy CE, O'Reilly K, Sweat M. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane HIV/AIDS Group, editor. Cochrane Database of Systematic Reviews. 2012 [cited 2020 Aug 7]. https://doi.wiley.com/10.1002/14651858.CD000124.pub4.

34. Keilson MV, Dworin FK, Gelso CJ. The effectiveness of time-limited psychotherapy in a university counseling center. J Clin Psychol. 1979;35:631–6.

35. Integrating Literacy, Culture, and Language to Improve Health Care Quality for Diverse Populations. [cited 2020 Oct 6]. https://www.ncbi.nlm.nih.gov/pubmed/3291931/.

36. Translation is not enough: cultural adaptation of health communication materials. European Centre for Disease Prevention and Control. 2016 [cited 2020 Oct 6]. https://ecdc.europa.eu/en/publications-data/translation-not-enough-cultural-adaptation-health-communication-materials.

37. Compaore S, Ouedraogo CMR, Koanda S, Haynatzki G, Chamberlain RM, Soliman AS. Barriers to cervical cancer screening in Burkina Faso: needs for patient and professional education. J Cancer Educ. 2016;31:760–6.

38. Binka C, Nyarko SH, Awusabo-Asare K, Doku DT. Barriers to the uptake of cervical cancer screening and treatment among rural women in Ghana. Biomed Res Int. 2019;2019:1–8.

39. Devarapalli P, Labani S, Nagarjuna N, Panchal P, Asthana S. Barriers affecting uptake of cervical cancer screening in low and middle income countries: a systematic review. Indian J Cancer. 2018;55:318.

40. Maza M, Melendez M, Masch R, Alfaro K, Chacon A, Gonzalez E, et al. Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El Salvador. Prev Med. 2018;114:149–55.

41. Committee on Improving the Quality of Health Care Globally, Board on Global Health, Board on Health Care Services, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Crossing the Global Quality Chasm: Improving Health Care Worldwide. Washington, D.C.: National Academies Press, 2018 [cited 2020 Oct 6]. https://www.nap.edu/catalog/25152.

42. Escamilla V, Calhoun L, Winston J, Speizer IS. The role of distance and quality on facility selection for maternal and child health services in urban Kenya. J Urban Health. 2018;95:1–12.

43. Abu-Sada C. La perception de MSF sur les terrains d'intervention : le cas du Niger. Humanitaire Enjeux, pratiques, débats. Médecins du monde; 2010 [cited 2020 Jun 18]. http://journals.openedition.org/humanitaire/704.

44. Burkina Faso. [cited 2020 Nov 3]. https://www.medicinsulmonde.org/en/countries/africa/burkina-faso.

45. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013;38:976–93.

46. Dudley L, Garner P. Strategies for integrating primary health services in low- and middle-income countries at the point of delivery. Cochrane Effective Practice and Organisation of Care Group, editor. Cochrane Database of Systematic Reviews. 2011 [cited 2020 Jun 19]. http://doi.wiley.com/10.1002/14651858.CD003318.pub3.

47. Church K, Warren CE, Birdthistle I, Ploubidis GB, Tomlin K, Zhou W, et al. Impact of integrated services on HIV testing: a nonrandomized trial among Kenyan family planning clients: impact of integrated services on HIV testing. Stud Fam Plann. 2017;48:201–18.

48. White RL, McGillicuddy A, Chowdhury R, Nuccio O. Integrating cervical cancer screening and preventive treatment with family planning and HIV-related services. Int J Gynecol Obstet. 2017;138:41–6.

49. Topp SM, Abimbola S, Joshi R, Negin J. How to assess and prepare health systems in low- and middle-income countries for integration of services—a systematic review. Health Policy Plan. 2018;33:298–312.

50. Grohar D, Vassilakos P, Benkorbi K, Tincho E, Kenfack B, Petignat P. Scaling up community-based cervical cancer screening in Cameroon employing a single visit approach. Int J Gynecol Cancer. 2020;30:1453–7.

51. Sayed S, Chung M, Temmerman M. Point-of-care HPV molecular diagnosis for patient and professional education. J Cancer Educ. 2016;31:760–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.